Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Direct Meds vs Midi Health

Direct Meds
Graded #19

Higher grade

vs+26.199999999999996
Midi Health
Graded #413

Lower grade

The verdict

Direct Meds takes it — 82.6/100 to 56.4/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +40
85
45
Dose & formulationDirect Meds +48
88
40
Clinical oversightDirect Meds +2
80
78
Labs & monitoringDirect Meds +26
78
52
FulfillmentDirect Meds +2
80
78
Contract termsDirect Meds +25
80
55
Direct Meds · left barMidi Health · right bar

The numbers

MetricDirect MedsMidi Health
WeighScore82.6/10056.4/100
GradeB−C
Scorecard rank#19#413
Semaglutide$179/moNot disclosed
Tirzepatide$224/moNot disclosed
CoverageNot publicly listedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed
Midi Health

Graded #413 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard